title: Uptake decrease of proliferative PET tracer 18FLT in bone marrow after carbon ion therapy in lung cancer.
abstract: OBJECTIVE
  The aim of this study was to investigate the change of 3'-[¹⁸F]fluoro-3'-deoxy-L: -thymidine (¹⁸FLT) uptake in normal bone marrow (BM) after inevitable radiation.
  
  
  METHODS
  Twenty-one non-small cell lung cancer patients who received carbon ion radiotherapy (CIRT) were studied with ¹⁸FLT-positron emission tomography/computed tomography (PET/CT) at pre- and post-CIRT. Radiation dose was calculated by radiation planning. Irradiated BM was divided into three groups (<10% of maximum dose, 10-30%, and >30%).
  
  
  RESULTS
  ¹⁸FLT uptake clearly decreased at >10% irradiated areas and mildly decreased at <10% areas. ¹⁸FLT uptake was lowest just after CIRT, somewhat increased at 3 months, and remained unchanged for more than 1 year. There was no significant difference between 10-30% and >30% areas.
  
  
  CONCLUSIONS
  ¹⁸FLT revealed that BM function decreased by small dose such as <4.2-4.4 GyE/1 fraction of CIRT and is eradicated by >4.2-4.4 GyE/1 fraction.
authors.affiliation: Diagnostic Imaging, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. mitsuru@nirs.go.jp.|Molecular Imaging Center, National Institute of Radiological Sciences, Anagawa 4-9-1, Inageku, Chiba, Japan. mitsuru@nirs.go.jp.
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Koizumi
authors.affiliation: Diagnostic Imaging, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Saga
authors.affiliation: Diagnostic Imaging, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Inubushi
authors.affiliation: Molecular Probe, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Fukumura
authors.affiliation: Molecular Imaging Center and Clinical Diagnosis Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
authors.forename: Kyosan
authors.initials: K
authors.lastname: Yoshikawa
authors.affiliation: Clinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
authors.forename: Naoyoshi
authors.initials: N
authors.lastname: Yamamoto
authors.affiliation: Clinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
authors.forename: Mio
authors.initials: M
authors.lastname: Nakajima
authors.affiliation: Clinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
authors.forename: Toshio
authors.initials: T
authors.lastname: Sugane
authors.affiliation: Clinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Baba
mesh_terms: D000368:Aged; D001853:Bone Marrow / Q000000981:diagnostic imaging* / Q000528:radiation effects*; D002244:Carbon / Q000627:therapeutic use*; D049109:Cell Proliferation; D003710:Demography; D015224:Dideoxynucleosides / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007477:Ions; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D014057:Tomography, X-Ray Computed
chemical_list: D015224:Dideoxynucleosides; D007477:Ions; D019275:Radiopharmaceuticals; D002244:Carbon; C002854:alovudine